Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $8.26M fell 14.3% year over year, behind the -2.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 11.3% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.

Context

  • Selling, general & admin amounted to 93.0% of revenue in FY2025, up 48.1 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $12.88M (-65.7%) for the fiscal year ending Dec 2026, a slowdown from the +4.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.26M-11.3% QoQ
Last fiscal yearDec 2025
$37.54M+4.5% YoY
LTMMar 2026
$36.17M-2.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-14.3%-72.0%-57.7 pp
1 year+4.5%-65.7%-70.2 pp
3-year CAGR+6.6%+2.9%-3.7 pp
5-year CAGR+7.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
37.54M USD
Year-over-year change
+4.5%
4-year CAGR
+0.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's LTM Mar 2026 selling, general & admin of $36.17M is the 6th highest of the 11 companies compared; the peer median is $35.74M.
  • Its year-over-year change of -2.1% is the 5th highest of 11, against a peer median of -10.7%.
  • Selling, general & admin amounts to 99.1% of revenue for VYGR, versus a peer median of 131.0%.
VYGR Competitors Peer median
Selling, General & Admin for VYGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M +54.0%+20.4%117.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$55.88M -11.2%-10.5%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M -11.6%+0.0%96.1%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.9M +4.0%+10.2%712.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M -25.4%-1.1%55.3%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$36.17M -2.1%+6.6%99.1%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M +76.0%+43.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M -34.0%-12.3%—
HUMAHumacyte, Inc.LTM Mar 2026$27.31M -10.2%+10.9%1354.8%
PYXSPyxis Oncology, Inc.LTM Mar 2026$20.02M -13.1%-15.9%144.4%
SGMTSagimet Biosciences Inc.LTM Mar 2026$18.03M +5.9%+42.7%—
Peer median (excluding VYGR) $35.74M-10.7%+5.1%131.0%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42M40.91M250.01M80M40.37M
Cost of Revenue73.79M55.76M92.17M00
Gross Profit(36.37M)(14.86M)157.84M80M40.37M
Gross Margin-97.2%-36.3%63.1%100.0%100.0%
Research & Development73.79M60.76M92.17M127.37M134.67M
Selling, General & Admin37.25M30.98M35.82M35.92M37.54M
Operating Expenses37.25M35.98M35.82M163.29M172.22M
Depreciation & Amortization5.17M6.19M4.44M4.73M4.06M
EBITDA(66.03M)(39.65M)138.18M(59.61M)(115.52M)
EBITDA Margin-176.5%-96.9%55.3%-74.5%-286.1%
Operating Income(73.62M)(50.84M)122.01M(83.29M)(131.84M)
Operating Margin-196.8%-124.3%48.8%-104.1%-326.6%
Interest Income01.79M11.72M18.33M10.62M
Interest Expense00000
Other Income / Expenses2.42M4.45M11.72M18.95M12.27M
Income Before Tax(71.2M)(46.39M)133.74M(64.34M)(119.58M)
Pre-Tax Margin-190.3%-113.4%53.5%-80.4%-296.2%
Income Tax Expense016K1.41M665K144K
Net Income(71.2M)(46.41M)132.33M(65M)(119.72M)
Net Margin-190.3%-113.4%52.9%-81.3%-296.5%
EPS (Basic)(1.75)(1.21)3.08(1.13)(2.04)
EPS (Diluted)(1.75)(1.21)2.97(1.13)(2.04)
Weighted Avg Shares37.67M38.36M43.02M57.67M58.69M
Weighted Avg Shares (Diluted)37.67M38.36M44.57M57.67M58.69M

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.